EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Cited by (1,066)

Items 1,001–1,066 of 1,066

1. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
   Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S. et al. · 2015 · Drugs
2. <i>PIK3CA</i> mutation is an early event in the development of endometriosis‐associated ovarian clear cell adenocarcinoma
   Yamamoto, Sohei, Tsuda, Hitoshi, Takano, Masashi, Iwaya, Keichi, Tamai, Seiichi, Matsubara, Osamu · 2011 · The Journal of Pathology
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
   Jänne, Pasi A., Johnson, Bruce E. · 2006 · Clinical Cancer Research
4. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response
   Gow, Chien-Hung, Chien, Chun-Ru, Chang, Yih-Leong, Chiu, Yueh-Hsia, Kuo, Sung-Hsin, Shih, Jin-Yuan, Chang, Yeun-Chung, Yu, Chong-Jen, Yang, Chih-Hsin, Yang, Pan-Chyr · 2008 · Clinical Cancer Research
5. <i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer
   Konduri, Kartik, Gallant, Jean-Nicolas, Chae, Young Kwang, Giles, Francis J., Gitlitz, Barbara J., Gowen, Kyle, Ichihara, Eiki, Owonikoko, Taofeek K., Peddareddigari, Vijay, Ramalingam, Suresh S. et al. · 2016 · Cancer Discovery
6. Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring <i>K-RAS</i> Mutations
   Konstantinidou, Georgia, Bey, Erik A., Rabellino, Andrea, Schuster, Katja, Maira, Michael S., Gazdar, Adi F., Amici, Augusto, Boothman, David A., Scaglioni, Pier Paolo · 2009 · Cancer Research
7. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis
   Lee, June-Koo, Hahn, Seokyung, Kim, Dong-Wan, Suh, Koung Jin, Keam, Bhumsuk, Kim, Tae Min, Lee, Se-Hoon, Heo, Dae Seog · 2014 · JAMA
8. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
   Yoshikawa, S, Kukimoto-Niino, M, Parker, L, Handa, N, Terada, T, Fujimoto, T, Terazawa, Y, Wakiyama, M, Sato, M, Sano, S et al. · 2013 · Oncogene
9. Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)
   Chen, Po-Han, Hu, Zhenyi, An, Elvira, Okeke, Ifunanya, Zheng, Sijin, Luo, Xuanmeng, Gong, Angela, Jaime-Figueroa, Saul, Crews, Craig M. · 2021 · ACS Chemical Biology
10. Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
    Shepherd, Frances A., Lacas, Benjamin, Le Teuff, Gwénaël, Hainaut, Pierre, Jänne, Pasi A., Pignon, Jean-Pierre, Le Chevalier, Thierry, Seymour, Lesley, Douillard, Jean-Yves, Graziano, Stephen et al. · 2017 · Journal of Clinical Oncology
11. EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
    Jia, Yong, Juarez, Jose, Li, Jie, Manuia, Mari, Niederst, Matthew J., Tompkins, Celin, Timple, Noelito, Vaillancourt, Mei-Ting, Pferdekamper, AnneMarie Culazzo, Lockerman, Elizabeth L. et al. · 2016 · Cancer Research
12. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
    Yen, Hsin-Yung, Liu, Ying-Chih, Chen, Nai-Yu, Tsai, Chia-Feng, Wang, Yi-Ting, Chen, Yu-Ju, Hsu, Tsui-Ling, Yang, Pan-Chyr, Wong, Chi-Huey · 2015 · Proceedings of the National Academy of Sciences
13. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
    Cho, Jeonghee, Chen, Liang, Sangji, Naveen, Okabe, Takafumi, Yonesaka, Kimio, Francis, Joshua M., Flavin, Richard J., Johnson, William, Kwon, Jihyun, Yu, Soyoung et al. · 2013 · Cancer Research
14. Oncogenic mutations as predictive factors in colorectal cancer
    Lièvre, A, Blons, H, Laurent-Puig, P · 2010 · Oncogene
15. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam, Bhumsuk, Kim, Dong-Wan, Park, Jin Hyun, Lee, Jeong-Ok, Kim, Tae Min, Lee, Se-Hoon, Chung, Doo Hyun, Heo, Dae Seog · 2014 · International Journal of Clinical Oncology
16. Finding the tumor copycat: Therapy fails, patients don’t
    Ellis, Lee M, Fidler, Isaiah J · 2010 · Nature Medicine
17. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
18. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations
    Shen, Yi-Cheng, Tseng, Guan-Chin, Tu, Chih-Yeh, Chen, Wei-Chun, Liao, Wei-Chih, Chen, Wei-Cheng, Li, Chia-Hsiang, Chen, Hung-Jen, Hsia, Te-Chun · 2017 · Lung Cancer
19. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
    Gong, Ke, Guo, Gao, Gerber, David E., Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D., Hatanpaa, Kimmo J., Kernstine, Kemp, Cai, Ling et al. · 2018 · Journal of Clinical Investigation
20. Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
    Lelais, Gérald, Epple, Robert, Marsilje, Thomas H., Long, Yun O., McNeill, Matthew, Chen, Bei, Lu, Wenshuo, Anumolu, Jaganmohan, Badiger, Sangamesh, Bursulaya, Badry et al. · 2016 · Journal of Medicinal Chemistry
21. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
    Arasada, Rajeswara Rao, Shilo, Konstantin, Yamada, Tadaaki, Zhang, Jianying, Yano, Seiji, Ghanem, Rashelle, Wang, Walter, Takeuchi, Shinji, Fukuda, Koji, Katakami, Nobuyuki et al. · 2018 · Nature Communications
22. Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
    Lee, Ho-June, Schaefer, Gabriele, Heffron, Timothy P., Shao, Lily, Ye, Xiaofen, Sideris, Steve, Malek, Shiva, Chan, Emily, Merchant, Mark, La, Hank et al. · 2013 · Cancer Discovery
23. <i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
    Hayashi, Takuo, Desmeules, Patrice, Smith, Roger S., Drilon, Alexander, Somwar, Romel, Ladanyi, Marc · 2018 · Clinical Cancer Research
24. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
    Hasako, Shinichi, Terasaka, Miki, Abe, Naomi, Uno, Takao, Ohsawa, Hirokazu, Hashimoto, Akihiro, Fujita, Ryoto, Tanaka, Kenji, Okayama, Takashige, Wadhwa, Renu et al. · 2018 · Molecular Cancer Therapeutics
25. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
    Xu, Xiao, Mao, Long, Xu, Wanhong, Tang, Wei, Zhang, Xiaoying, Xi, Biao, Xu, Rongda, Fang, Xin, Liu, Jia, Fang, Ce et al. · 2016 · Molecular Cancer Therapeutics
26. Role of imaging in the era of precision medicine
    Giardino, Angela, Gupta, Supriya, Olson, Emmi, Sepulveda, Karla, Lenchik, Leon, Ivanidze, Jana, Rakow-Penner, Rebecca, Patel, Midhir J., Subramaniam, Rathan M., Ganeshan, Dhakshinamoorthy · 2017 · Academic Radiology
27. PROTAC therapy as a new targeted therapy for lung cancer
    Li, Jennifer W., Zheng, Guangrong, Kaye, Frederic J., Wu, Lizi · 2023 · Molecular Therapy
28. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
    Yuza, Yuki, Glatt, Karen A., Jiang, Jingrui, Greulich, Heidi, Minami, Yuko, Woo, Michele S., Shimamura, Takeshi, Shapiro, Geoffrey I., Lee, Jeffrey C., Ji, Hongbin et al. · 2007 · Cancer Biology &amp; Therapy
29. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
    Mak, K. S., Gainor, J. F., Niemierko, A., Oh, K. S., Willers, H., Choi, N. C., Loeffler, J. S., Sequist, L. V., Shaw, A. T., Shih, H. A. · 2015 · Neuro-Oncology
30. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
    Gong, Meiling, Li, Yan, Ye, Xiaoping, Zhang, Linlin, Wang, Zhifang, Xu, Xiaowen, Shen, Yejing, Zheng, Cuixia · 2020 · Cell Communication and Signaling
31. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling
    Quinn, Brendan J., Dallos, Matthew, Kitagawa, Hiroshi, Kunnumakkara, Ajaikumar B., Memmott, Regan M., Hollander, M. Christine, Gills, Joell J., Dennis, Phillip A. · 2013 · Cancer Prevention Research
32. Opportunities and challenges in combination gene cancer therapy
    Nastiuk, Kent L., Krolewski, John J. · 2016 · Advanced Drug Delivery Reviews
33. Epithelial-mesenchymal transition orchestrates tumor microenvironment: Current perceptions and challenges
    Xie, Yuqi, Wang, Xuan, Wang, Wenquan, Pu, Ning, Liu, Liang · 2025 · Journal of Translational Medicine
34. Clinicopathologic characteristics of <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> alterations in 6,595 lung cancers
    Lee, Boram, Lee, Taebum, Lee, Se-Hoon, Choi, Yoon-La, Han, Joungho · 2016 · Oncotarget
35. Sample features associated with success rates in population-based EGFR mutation testing
    Shiau, Carolyn J., Babwah, Jesse P., da Cunha Santos, Gilda, Sykes, Jenna R., Boerner, Scott L., Geddie, William R., Leighl, Natasha B., Wei, Cuihong, Kamel-Reid, Suzanne, Hwang, David M. et al. · 2014 · Journal of Thoracic Oncology
36. NSCLC and HER2: between lights and shadows
    Ricciardi, Giuseppina Rosaria Rita, Russo, Alessandro, Franchina, Tindara, Ferraro, Giuseppa, Zanghì, Mariangela, Picone, Antonio, Scimone, Antonino, Adamo, Vincenzo · 2014 · Journal of Thoracic Oncology
37. Targeting Ras in myeloid leukemias
    Braun, Benjamin S., Shannon, Kevin · 2008 · Clinical Cancer Research
38. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study
    Kubota, Kaoru, Kawahara, Masaaki, Ogawara, Mitsumasa, Nishiwaki, Yutaka, Komuta, Kiyoshi, Minato, Koichi, Fujita, Yuka, Teramukai, Satoshi, Fukushima, Masanori, Furuse, Kiyoyuki · 2008 · The Lancet Oncology
39. Evaluation of Alternative <i>In Vivo</i> Drug Screening Methodology: A Single Mouse Analysis
    Murphy, Brendan, Yin, Han, Maris, John M., Kolb, E. Anders, Gorlick, Richard, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Kurmasheva, Raushan T., Dvorchik, Igor et al. · 2016 · Cancer Research
40. A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
    Liao, Sida, Davoli, Teresa, Leng, Yumei, Li, Mamie Z., Xu, Qikai, Elledge, Stephen J. · 2017 · Genes &amp; Development
41. Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
    Chung, Kuei-Pin, Wu, Shang-Gin, Wu, Jenn-Yu, Yang, James Chih-Hsin, Yu, Chong-Jen, Wei, Pin-Fei, Shih, Jin-Yuan, Yang, Pan-Chyr · 2012 · Clinical Cancer Research
42. Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway
    Kometani, Takuro, Yoshino, Ichiro, Miura, Naoko, Okazaki, Hiroshi, Ohba, Taro, Takenaka, Tomoyoshi, Shoji, Fumihiro, Yano, Tokujiro, Maehara, Yoshihiko · 2009 · Cancer Letters
43. Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
    Heppner, David E., Wittlinger, Florian, Beyett, Tyler S., Shaurova, Tatiana, Urul, Daniel A., Buckley, Brian, Pham, Calvin D., Schaeffner, Ilse K., Yang, Bo, Ogboo, Blessing C. et al. · 2022 · ACS Medicinal Chemistry Letters
44. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
    Choi, Yun Jung, Rho, Jin Kyung, Jeon, Byung-suk, Choi, Su Jin, Park, Su Cheol, Lee, Seung Sook, Kim, Hye-Ryoun, Kim, Cheol Hyeon, Lee, Jae Cheol · 2010 · Cancer Chemotherapy and Pharmacology
45. Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Zer, Alona, Ding, Keyue, Lee, Siow Ming, Goss, Glenwood D., Seymour, Lesley, Ellis, Peter M., Hackshaw, Allan, Bradbury, Penelope A., Han, Lei, O’Callaghan, Christopher J. et al. · 2016 · Journal of Thoracic Oncology
46. AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo
    Xie, Hua, Lin, Liping, Tong, Linjiang, Jiang, Yong, Zheng, Mingyue, Chen, Zhuo, Jiang, Xiaoyan, Zhang, Xiaowei, Ren, Xiaowei, Qu, Wenchao et al. · 2011 · PLoS ONE
47. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR
    Basu, Debjit, Richters, André, Rauh, Daniel · 2015 · Bioorganic &amp; Medicinal Chemistry
48. Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
    Bertotti, Andrea, Sassi, Francesco · 2015 · Clinical Cancer Research
49. Structural basis of mutant-selectivity and drug-resistance related to CO-1686
    Yan, Xiao-E, Zhu, Su-Jie, Liang, Ling, Zhao, Peng, Choi, Hwan Geun, Yun, Cai-Hong · 2017 · Oncotarget
50. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
    Wu, Jenn-Yu, Shih, Jin-Yuan · 2016 · OncoTargets and Therapy
51. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
    Venugopalan, Abhilash, Lee, Min-Jung, Niu, Gang, Medina-Echeverz, José, Tomita, Yusuke, Lizak, Martin J., Cultraro, Constance M., Simpson, Robert Mark, Chen, Xiaoyuan, Trepel, Jane B. et al. · 2016 · Oncotarget
52. Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
    Schadt, Eric E., Buchanan, Sean, Brennand, Kristen J., Merchant, Kalpana M. · 2014 · Frontiers in Pharmacology
53. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
    Yap, Timothy A., Macklin-Doherty, Aislinn, Popat, Sanjay · 2017 · European Journal of Cancer
54. Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer
    Eskander, Mariam F., Gil, Lindsay, Beal, Eliza W., Li, Yaming, Hamad, Ahmad, Oppong, Bridget, Obeng-Gyasi, Samilia, Tsung, Allan · 2022 · Annals of Surgical Oncology
55. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade
    Kasper, S, Breitenbuecher, F, Reis, H, Brandau, S, Worm, K, Köhler, J, Paul, A, Trarbach, T, Schmid, K W, Schuler, M · 2013 · Oncogene
56. Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
    Hampton, Kaia K., Craven, Rolf J. · 2014 · Oncoscience
57. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels
    Iivanainen, Erika, Lauttia, Susanna, Zhang, Na, Tvorogov, Denis, Kulmala, Jarmo, Grenman, Reidar, Salven, Petri, Elenius, Klaus · 2009 · Microvascular Research
58. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
    Han, Luwei, Zhang, Xiaomeng, Wang, Zhiqiang, Zhang, Xian, Zhao, Liwen, Fu, Wei, Liang, Xiaobo, Zhang, Zhibo, Wang, Yong · 2021 · Frontiers in Pharmacology
59. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
    Chen, Kaiyan, Yu, Xiaoqing, Wang, Haiyang, Huang, Zhiyu, Xu, Yanjun, Gong, Lei, Fan, Yun · 2017 · Cancer Chemotherapy and Pharmacology
60. Dacomitinib in lung cancer: a &amp;ldquo;lost generation&amp;rdquo; EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou, Sai-Hong, Soo, Ross · 2015 · Drug Design, Development and Therapy
61. Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
    Funingana, Ionut-Gabriel, Reinius, Marika A.V., Petrillo, Angelica, Ang, Joo Ern, Brenton, James D. · 2021 · Seminars in Cancer Biology
62. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
    Liu, Xiaoke, Hong, Lingzhi, Nilsson, Monique, Hubert, Shawna Marie, Wu, Shuhong, Rinsurongkawong, Waree, Lewis, Jeffery, Spelman, Amy, Roth, Jack, Swisher, Steven et al. · 2020 · Lung Cancer
63. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: similarities and main differences for prognosis and therapies
    Giopanou, Ioanna, Pintzas, Alexandros · 2020 · Critical Reviews in Oncology/Hematology
64. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
    Oh, Hwanhee, Hwang, Inah, Jang, Ja-Young, Wu, Lingxiang, Cao, Dongqing, Yao, Jun, Ying, Haoqiang, Li, Jian Yi, Yao, Yu, Hu, Baoli et al. · 2021 · Cancer Research
65. Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
    OIKAWA, TAKEFUMI, OHIRA, TATSUO, OTANI, KEISHI, HAGIWARA, MASARU, KONAKA, CHIMORI, IKEDA, NORIHIKO · 2015 · Molecular and Clinical Oncology
66. Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer
    Wang, Shuhang, An, Tongtong, Duan, Jianchun, Zhang, Lijian, Wu, Meina, Zhou, Qinghua, Chen, Jinfeng, Zhuo, Minglei, Yang, Lu, Wang, Yuyan et al. · 2013 · PLoS ONE